Subcutaneous immunoglobulin program launches

April 16, 2007

An educational program is now available to help patients learn to self-administer Vivaglobin, the first subcutaneously administered immunoglobulin for the treatment of primary immunodeficiency.

An educational program is now available to help patients learn to self-administer Vivaglobin, the first subcutaneously administered immunoglobulin for the treatment of primary immunodeficiency. Derived from human plasma, the replacement therapy is delivered directly under the skin via a small portable pump and can be administered at home. Manufacturer CSL Behring will provide a starter kit for all new patients that will contain administration guides, product information, and a treatment journal. Specialty pharmacies contracted to dispense the product will provide training, infusion pump, needles, tubing, and additional supplies needed for treatment. According to the manufacturer, new patients will require four or five educational lessons with a nurse prior to performing self-administration independently. More information about the program, named VITAL (Vivaglobin Integrated Training and Learning), can be accessed on-line at